Publications by authors named "Craig Reynolds"

32Publications

Caring for the Older Population With Advanced Lung Cancer.

Am Soc Clin Oncol Educ Book 2017 ;37:587-596

From the VA Connecticut Cancer Center and Yale Cancer Center, West Haven and New Haven, CT; Florida Cancer Specialists and Research Institute, Ocala, FL; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_179850DOI Listing
November 2017

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Oncologist 2015 Oct 1;20(10):1175-81. Epub 2015 Sep 1.

Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591939PMC
October 2015

Beyond "second-line" in non-small cell lung cancer: therapy and supportive care.

Am Soc Clin Oncol Educ Book 2015 :e414-8

From Seattle Cancer Care Alliance, University of Washington, Seattle, WA; US Oncology Research, Ocala, FL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e414DOI Listing
February 2016

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

J Thorac Oncol 2015 Feb;10(2):353-9

*Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; †Feinberg School of Medicine, Northwestern University, Chicago, IL; ‡Ocala Oncology, Ocala, FL and US Oncology Research, Inc., Houston, TX; §David Geffen School of Medicine at UCLA/Translational Research in Oncology-US, Los Angeles, CA; ║Northwest Georgia Oncology Centers, Marietta, GA; ¶Washington University School of Medicine, St. Louis, MO; #Tulsa Cancer Institute, Tulsa, OK; **Eli Lilly and Company, Indianapolis, IN; ††University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and ‡‡Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000277DOI Listing
February 2015

Natural killer activity: early days, advances, and seminal observations.

Crit Rev Oncog 2014 ;19(1-2):1-13

Offlce of the Director, National Cancer Institute, National Institutes of Health.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272325PMC
http://dx.doi.org/10.1615/critrevoncog.2014011125DOI Listing
September 2014

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

J Clin Oncol 2013 Dec 21;31(34):4349-57. Epub 2013 Oct 21.

Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.9626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367PMC
December 2013

Interactive evolution of camouflage.

Authors:
Craig Reynolds

Artif Life 2011 3;17(2):123-36. Epub 2011 Mar 3.

Sony Computer Entertainment, US R&D, Foster City, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1162/artl_a_00023DOI Listing
June 2011

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

Nat Med 2005 Sep 21;11(9):986-91. Epub 2005 Aug 21.

Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1290DOI Listing
September 2005